Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiCharge TM – at BioProcess International 2024 New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea , Sept. 25, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), launched today a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.
S-AfuCHO TM , introduced at BioProcess International 2024, is a cell line platform that can generate afucosylated antibodies that exhibit enhanced antibody-dependent cellular cytotoxity (ADCC) activity for increased therapeutic efficacy. The platform removes the core fucose from Fc N-glycans through knockout of the host (FUT8) gene to achieve higher ADCC activity while retaining desired titers, stability, and product quality (Figure 1) . S-OptiCharge TM is an upstream process platform that can modulate a molecule's charge variant distribution.
Modifications can occur at any step of the manufacturing process, impacting product safety and efficacy. The platform minimizes charged variants within samples while maximizing the main molecular form to ensure safe therapeutic effects. By optimizing media, additives, and process parameters and using a thorough screening procedure, S-OptiCharge TM ensures high product quality th.